Palisade Bio Inc (PALI)

$1.83 +0.02 (1.10%)
Market Cap 314.18M
Revenue (ttm) 0.00
Net Income (ttm) -16.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,810,000
Avg Vol 3,994,106
Day's Range N/A - N/A
Shares Out 173.58M
Stochastic %K 15%
Beta 1.52
Analysts Strong Sell
Price Target $10.00

Company Profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant Pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 704 4900
Address:
4600 South Syracuse Street, Suite 900, Denver, United States
MNJ7777777
MNJ7777777 May. 13 at 2:29 PM
$PALI MXCT announced a share repurchase program this morning.
0 · Reply
Readcarefully
Readcarefully May. 13 at 9:53 AM
$PALI Very good news: "As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 CD that is expected in early 2028." https://finance.yahoo.com/news/palisade-bio-reports-first-quarter-201500467.html
0 · Reply
buymoremakemore
buymoremakemore May. 12 at 11:29 PM
$PALI I am from the Pacific Palisades. My house burnt down last year. Let’s not burn down another Palisades with this shelf BS
0 · Reply
TwongStocks
TwongStocks May. 12 at 9:52 PM
$PALI $300M shelf registration statement filed https://www.sec.gov/Archives/edgar/data/1357459/000149315226022548/forms-3.htm
0 · Reply
d_risk
d_risk May. 12 at 8:28 PM
$PALI - PALISADE BIO, INC. - 10Q - Updated Risk Factors PALI’s 10-Q sharpens its “all eggs in one basket” risk: the company now squarely ties its survival to PALI-2108, stressing fragile licensing, foreign trial data risk, heavy funding needs, third‑party dependencies, shifting healthcare law and pricing pressure, and its lack of any approved products or proven commercial model. #Biotechnology #ClinicalTrialsRisk #RegulatoryUncertainty #FundingDependency #HealthcarePricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/PALI/10-Q/2026-05-12
0 · Reply
TwongStocks
TwongStocks May. 12 at 8:17 PM
$PALI 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000135745926000010/pali-20260331.htm • 173,579,670 shares outstanding as of May 7 • $132.6M as of Mar 31
1 · Reply
BOUDIN420
BOUDIN420 May. 8 at 7:50 PM
$PALI soaking these at $1.80
0 · Reply
companyofone
companyofone May. 8 at 7:03 PM
$PALI voted against adding another 150 million shares like wtf
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 7 at 3:24 PM
$PALI RSI: 36.78, MACD: -0.0074 Vol: 0.24, MA20: 2.14, MA50: 1.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Readcarefully
Readcarefully May. 7 at 6:50 AM
$PALI This is new: "Precision Medicine CDx test in development to identify UC patient responders to PDE4 inhibitors, ensuring better treatment outcomes" That would be totally disruptive and increase the market value x3 https://d2ghdaxqb194v2.cloudfront.net/2827/199934.pdf
1 · Reply
Latest News on PALI
Palisade Bio files $300M mixed securities shelf

2026-05-12T22:21:57.000Z - 3 days ago

Palisade Bio files $300M mixed securities shelf

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

May 12, 2026, 4:15 PM EDT - 3 days ago

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

May 5, 2026, 8:30 AM EDT - 10 days ago

Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis

Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 16, 2026, 2:15 PM EDT - 4 weeks ago

Palisade Bio Transcript: 25th Annual Needham Virtual Healthcare Conference

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Apr 16, 2026, 8:50 AM EDT - 4 weeks ago

Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026

Palisade Bio initiated with an Outperform at Wolfe Research

2026-04-08T20:43:15.000Z - 5 weeks ago

Palisade Bio initiated with an Outperform at Wolfe Research

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Apr 8, 2026, 9:00 AM EDT - 5 weeks ago

Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

2026-03-31T20:38:39.000Z - 6 weeks ago

Palisade Bio reaction to PALI-2108 data ‘looks misaligned’, says Clear Street

Palisade Bio Transcript: Study result

Mar 31, 2026, 8:00 AM EDT - 6 weeks ago

Palisade Bio Transcript: Study result

Palisade Bio announces topline data from PALI-2108 trial

2026-03-30T20:19:16.000Z - 6 weeks ago

Palisade Bio announces topline data from PALI-2108 trial

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

Mar 30, 2026, 4:01 PM EDT - 6 weeks ago

Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn's Disease

Palisade Bio initiated with a Buy at H.C. Wainwright

2026-03-26T10:11:33.000Z - 7 weeks ago

Palisade Bio initiated with a Buy at H.C. Wainwright

Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 3:10 PM EST - 2 months ago

Palisade Bio Transcript: TD Cowen 46th Annual Health Care Conference

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Mar 2, 2026, 9:00 AM EST - 2 months ago

Palisade Bio Announces Participation in Two Upcoming Investor Conferences

Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 12:40 PM EST - 2 months ago

Palisade Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Palisade Bio initiated with a Buy at Stifel

2026-02-24T21:52:07.000Z - 2 months ago

Palisade Bio initiated with a Buy at Stifel

Palisade Bio announces presentation of new data for PALI-2108

2026-02-23T13:47:18.000Z - 2 months ago

Palisade Bio announces presentation of new data for PALI-2108

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Feb 23, 2026, 8:40 AM EST - 2 months ago

Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

Palisade Bio appoints Verstockt to its Clinical Advisory Board

2026-02-17T14:05:21.000Z - 3 months ago

Palisade Bio appoints Verstockt to its Clinical Advisory Board

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Feb 17, 2026, 8:45 AM EST - 3 months ago

Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 9, 2026, 9:00 AM EST - 3 months ago

Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 5, 2026, 8:45 AM EST - 3 months ago

Palisade Bio to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

2026-01-29T13:50:44.000Z - 3 months ago

Palisade Bio appoints Peyrin-Biroulet, Rubin to Clinical Advisory Board

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Jan 29, 2026, 8:45 AM EST - 3 months ago

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Jan 16, 2026, 8:30 AM EST - 4 months ago

Palisade Bio Announces Two Abstracts Selected for Poster Presentations at Leading Global Inflammatory Bowel Disease Conferences

Palisade Bio initiated with a Buy at B. Riley

2026-01-09T10:35:21.000Z - 4 months ago

Palisade Bio initiated with a Buy at B. Riley

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

2026-01-07T13:25:34.000Z - 4 months ago

Palisade Bio announces equity investment from Crohn’s & Colitis Foundation

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Jan 7, 2026, 8:15 AM EST - 4 months ago

Palisade Bio Announces Strategic Equity Investment from the Crohn's & Colitis Foundation's IBD Ventures Program to Advance PALI-2108

Palisade Bio granted Japanese patent covering PALI-2108

2025-12-30T13:45:55.000Z - 4 months ago

Palisade Bio granted Japanese patent covering PALI-2108

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Dec 30, 2025, 8:35 AM EST - 4 months ago

Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108

Palisade Bio initiated with a Buy at Clear Street

2025-12-29T21:10:18.000Z - 4 months ago

Palisade Bio initiated with a Buy at Clear Street

Palisade Bio initiated with an Overweight at Piper Sandler

2025-12-29T09:30:14.000Z - 4 months ago

Palisade Bio initiated with an Overweight at Piper Sandler

Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 10:30 AM EST - 5 months ago

Palisade Bio Transcript: Piper Sandler 37th Annual Healthcare Conference

Palisade Bio appoints James Izanec as VP, clinical development

2025-12-02T13:55:38.000Z - 5 months ago

Palisade Bio appoints James Izanec as VP, clinical development

BMY

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Dec 2, 2025, 8:45 AM EST - 5 months ago

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:45 AM EST - 6 months ago

Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference

Palisade Bio price target raised to $8 from $2 at Maxim

2025-11-11T17:45:32.000Z - 6 months ago

Palisade Bio price target raised to $8 from $2 at Maxim

Palisade Bio appoints Sharon Skare as global head, clinical operations

2025-10-28T12:50:12.000Z - 7 months ago

Palisade Bio appoints Sharon Skare as global head, clinical operations

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Oct 28, 2025, 8:45 AM EDT - 7 months ago

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

Palisade Bio announces first patients dosed in Phase 1b study of PALI-2108

2025-10-20T12:52:57.000Z - 7 months ago

Palisade Bio announces first patients dosed in Phase 1b study of PALI-2108

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Oct 20, 2025, 8:45 AM EDT - 7 months ago

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio granted Canadian patent covering PALI-2108 composition

2025-10-13T12:50:05.000Z - 7 months ago

Palisade Bio granted Canadian patent covering PALI-2108 composition

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Oct 13, 2025, 8:45 AM EDT - 7 months ago

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Oct 9, 2025, 5:00 PM EDT - 7 months ago

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Oct 2, 2025, 4:05 PM EDT - 8 months ago

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Oct 1, 2025, 9:20 AM EDT - 8 months ago

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Sep 26, 2025, 4:05 PM EDT - 8 months ago

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Sep 17, 2025, 9:00 AM EDT - 8 months ago

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Sep 5, 2025, 8:45 AM EDT - 9 months ago

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn's Disease (FSCD)

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Aug 25, 2025, 9:00 AM EDT - 9 months ago

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Aug 7, 2025, 9:15 AM EDT - 10 months ago

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Jul 31, 2025, 8:45 AM EDT - 10 months ago

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Jul 23, 2025, 8:00 PM EDT - 10 months ago

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 10 months ago

Palisade Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Jul 9, 2025, 8:45 AM EDT - 11 months ago

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

May 27, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

May 6, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

May 1, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio's AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Apr 9, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Mar 14, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Mar 12, 2025, 8:30 AM EDT - 1 year ago

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Mar 4, 2025, 8:30 AM EST - 1 year ago

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Feb 20, 2025, 8:45 AM EST - 1 year ago

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Palisade Bio Transcript: Virtual Investor "Top 5 for '25"

Feb 19, 2025, 9:00 AM EST - 1 year ago

Palisade Bio Transcript: Virtual Investor "Top 5 for '25"

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Feb 10, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Jan 29, 2025, 8:45 AM EST - 1 year ago

Palisade Bio Selected for Poster Presentation at the 2025 Crohn's & Colitis Congress

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 3, 2025, 5:20 PM EST - 1 year ago

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Dec 17, 2024, 8:30 AM EST - 1 year ago

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 13, 2024, 4:05 PM EST - 1 year ago

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Dec 12, 2024, 12:05 PM EST - 1 year ago

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Dec 3, 2024, 8:15 AM EST - 1 year ago

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Nov 21, 2024, 8:15 AM EST - 1 year ago

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Nov 12, 2024, 8:45 AM EST - 1 year ago

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

MNJ7777777
MNJ7777777 May. 13 at 2:29 PM
$PALI MXCT announced a share repurchase program this morning.
0 · Reply
Readcarefully
Readcarefully May. 13 at 9:53 AM
$PALI Very good news: "As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 CD that is expected in early 2028." https://finance.yahoo.com/news/palisade-bio-reports-first-quarter-201500467.html
0 · Reply
buymoremakemore
buymoremakemore May. 12 at 11:29 PM
$PALI I am from the Pacific Palisades. My house burnt down last year. Let’s not burn down another Palisades with this shelf BS
0 · Reply
TwongStocks
TwongStocks May. 12 at 9:52 PM
$PALI $300M shelf registration statement filed https://www.sec.gov/Archives/edgar/data/1357459/000149315226022548/forms-3.htm
0 · Reply
d_risk
d_risk May. 12 at 8:28 PM
$PALI - PALISADE BIO, INC. - 10Q - Updated Risk Factors PALI’s 10-Q sharpens its “all eggs in one basket” risk: the company now squarely ties its survival to PALI-2108, stressing fragile licensing, foreign trial data risk, heavy funding needs, third‑party dependencies, shifting healthcare law and pricing pressure, and its lack of any approved products or proven commercial model. #Biotechnology #ClinicalTrialsRisk #RegulatoryUncertainty #FundingDependency #HealthcarePricingPressure 🟢 Added 🟠 Removed https://d-risk.ai/PALI/10-Q/2026-05-12
0 · Reply
TwongStocks
TwongStocks May. 12 at 8:17 PM
$PALI 10-Q filed https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000135745926000010/pali-20260331.htm • 173,579,670 shares outstanding as of May 7 • $132.6M as of Mar 31
1 · Reply
BOUDIN420
BOUDIN420 May. 8 at 7:50 PM
$PALI soaking these at $1.80
0 · Reply
companyofone
companyofone May. 8 at 7:03 PM
$PALI voted against adding another 150 million shares like wtf
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 7 at 3:24 PM
$PALI RSI: 36.78, MACD: -0.0074 Vol: 0.24, MA20: 2.14, MA50: 1.98 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Readcarefully
Readcarefully May. 7 at 6:50 AM
$PALI This is new: "Precision Medicine CDx test in development to identify UC patient responders to PDE4 inhibitors, ensuring better treatment outcomes" That would be totally disruptive and increase the market value x3 https://d2ghdaxqb194v2.cloudfront.net/2827/199934.pdf
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 7 at 3:50 AM
$PALI RSI: 40.57, MACD: 0.0024 Vol: 0.24, MA20: 2.14, MA50: 1.98 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Readcarefully
Readcarefully May. 6 at 6:42 AM
$PALI Why PALI will continue to show better results than Mufemilast. Mufemilast already shows exceptional results in UC, but PALI is even better because: 1. Local activation because of the prodrug mechanism --> higher concentration of the medication in the inflamed tissue 2. Less adverse events --> higher dosages possible 3. Longer half life --> more stable and constant PDE4-inhibition 4. Faster respons of the biomarkers --> predictor of higher remission
0 · Reply
100K2022
100K2022 May. 5 at 8:00 PM
$PALI what’s going on here?
1 · Reply
SkywalkerAR
SkywalkerAR May. 5 at 5:42 PM
$PALI https://palisadebio.com/palisade-bio-reports-additional-phase-1a-b-data-demonstrating-colon-targeted-exposure-and-sustained-ic90-coverage-supporting-once-daily-dosing-in-ulcerative-colitis/
0 · Reply
Unicorno
Unicorno May. 5 at 3:27 PM
$PALI mufemilast data confirm pde4 very effective in UC just presented at DDW! mufemilast data ill remain in china so palisade green light
0 · Reply
DARKP00L
DARKP00L May. 5 at 12:38 PM
$PALI 08:36 on May. 05 2026 Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026 #tradeideas
0 · Reply
SkywalkerAR
SkywalkerAR May. 5 at 6:41 AM
$PALI https://x.com/chaotropy/status/2051333537865884087
1 · Reply
georgeyann
georgeyann May. 5 at 12:25 AM
$PALI now 2k shares! Hope $3.0 soon
0 · Reply
oneyedjacks
oneyedjacks May. 4 at 11:27 PM
$PALI GI conf tomorrow!!
0 · Reply
BillionerOfKing
BillionerOfKing May. 4 at 11:24 AM
$PALI Current Stock Price: $2.00
0 · Reply
georgeyann
georgeyann May. 1 at 12:40 AM
$PALI now 1500 shares total
1 · Reply
TwongStocks
TwongStocks Apr. 29 at 8:58 PM
$PALI Definitive proxy field for Annual Meeting. Date is set for June 10, 2026. https://www.sec.gov/ix?doc=/Archives/edgar/data/1357459/000149315226019629/formdef14a.htm All proposals similar to what was disclosed in the preliminary proxy on Apr 17. Record date is Apr 15. As of the record date, there were 167,424,202 shares outstanding and entitled to vote.
0 · Reply